MedTrace Logo

Eosinopenia in Severe COPD Exacerbation

NCT06188065 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-04-14

No results posted yet for this study

Summary

The goals of this observational study are to identify factors independently associated with admission eosinopenia in patients with a severe exacerbation of chronic obstructive pulmonary disease (COPD) and to determine when blood eosinophil count (BEC) will recover to baseline stable state in patients who are admitted to hospital with a severe exacerbation of COPD and associated eosinopenia.

The main aims of the study are to:

1. Identify demographic, physiological and clinical factors independently associated with admission eosinopenia in patients with a severe exacerbation of COPD
2. Assess the time to recovery from eosinopenia to stable BEC following a severe exacerbation of COPD

Conditions

Interventions

DIAGNOSTIC_TEST

Blood eosinophil count

To determine the time it takes for blood eosinophil count to recover to baseline stable state following severe exacerbation of COPD associated with admission eosinopenia and to explore independent factors associated with admission eosinopenia.

Sponsors & Collaborators

  • Newcastle University

    collaborator OTHER

  • Chiesi UK

    collaborator INDUSTRY

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Northumbria Healthcare NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Stephen Bourke, MBChB, PhD · Northumbria Healthcare NHS Foundation Trust

  • Peter Ireland, MBBS · Northumbria Healthcare NHS Foundation Trust

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-22
Primary Completion
2026-07-31
Completion
2026-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06188065 on ClinicalTrials.gov